Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 365 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March February 24, 2025 Expanding Research on Dormant Cancer Cells Aims to Prevent Metastasis April 10, 2025 Targeted Drug Erdafitinib Benefits Some Patients with Advanced Bladder Cancer August 9, 2019 Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True September 27, 2021 Load more HOT NEWS Breast Cancer Survivor Opens Her Own Business 17 Years After Beating... TP53 Allelic State is Critical in Myelodysplastic Syndromes EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab A celebration of peer review
